Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.1352W HIGH $13.02
Volume
236.55 K
Value Traded
6.28 M
Short % Float
22.67%
+2.64%Week
-9.23%1 Month
-12.14%3 Month
+1.93%6 Month
+18.22%5 Year
-50.13%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
575.23 M
EPS (TTM)
2.40
P/E Ratio
3.07
Ent. Value
316.20 M
Total Shares
77.97 M
Float Shares
71.48 M
Insiders
8.29%
Institutions
56.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CRMD Catalyst Timeline
Dated clinical, regulatory and corporate events for CorMedix Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for CorMedix Inc.
541Total events
9Upcoming
141Tier-1 (high impact)
2012 to 2033Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseDefenCathApprovedCorporate
New multi-year commercial supply agreement with Large Dialysis Operator
▲Runway Guidance UpdateCorporate
FY 2026 revenue guidance maintained, adjusted EBITDA guidance raised
◆Timing GuidanceREZZAYOPresentation
sNDA submission for REZZAYO prophylaxis indication expected in Q3 2026
prophylaxis of invasive fungal diseasesource ↗
◆Timing GuidancePresentation
Anticipated changes to add-on payments in year 3 of TDAPA (Q3 2026 - Q2 2027)
▲IP Litigation RulingMinocinIP / Competition
Federal Circuit affirms district court ruling that MINOCIN patents are valid and infringed by Nexus generic
serious and drug-resistant infectionssource ↗
◆Oral PresentationPresentation
RBC Capital Markets Global Healthcare Conference fireside chat
●Protocol AmendmentDefenCathApprovedTrial
Protocol amendment submitted to FDA to broaden enrollment for TPN study
catheter-related bloodstream infections in TPN patientssource ↗
●Oral PresentationPresentation
Conference call to discuss Q1 2026 results and business update
▲Topline ReadoutREZZAYOClinical Data
Positive topline results from Phase III ReSPECT trial of REZZAYO for prophylaxis of IFD in allogeneic HSCT
prophylaxis of invasive fungal diseases in allogeneic hematopoietic stem cell transplantationsource ↗
◆Oral PresentationPresentation
CorMedix management to participate in fireside chat at Needham Virtual Healthcare Conference
◆Topline ReadoutREZZAYOClinical Data
Topline Results for REZZAYO Phase III Study in IFD Prophylaxis
prophylaxis of invasive fungal disease in adult patients undergoing allogeneic bone marrow transplantsource ↗
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Investor Meetings
●Oral PresentationPresentation
Conference call to discuss corporate developments and financial results
◆Oral PresentationPresentation
CorMedix to present at 44th Annual J.P. Morgan Healthcare Conference
▲Quarterly UpdateCorporate
Preliminary Q4 2025 net revenue of ~$127M and FY 2025 pro forma net revenue of ~$400M
◆Trial CompletionREZZAYOTrial
Phase 3 study for REZZAYO prophylaxis expected to complete in 1H 2026
prophylaxis of invasive fungal infections in adults undergoing allogeneic blood and marrow transplantationsource ↗
▲Full ResultsDefenCathApprovedClinical Data
Interim results from real-world evidence study of DefenCath showing 72% reduction in CRBSI and 70% reduction in hospitalizations
catheter-related bloodstream infections in hemodialysis patientssource ↗
◆Interim AnalysisDefenCathApprovedTrial
Interim data from real world evidence study expected around year-end
catheter-related bloodstream infections in hemodialysissource ↗
◆Trial CompletionNiyadTrial
Talphera expects to complete Phase 3 NEPHRO CRRT study by end of 2025
anticoagulation for continuous renal replacement therapy (CRRT)source ↗
▲Other Regulator MilestoneDefenCathApprovedEx-US Regulatory
DefenCath receives Innovative Technology designation from Vizient
catheter-related bloodstream infections in hemodialysissource ↗
▲Quarterly UpdateCorporate
Preliminary Q3 2025 net revenue of more than $125 million pro forma and more than $85 million DefenCath
◆Quarterly UpdateDefenCathApprovedCorporate
Q4 2025 DefenCath sales of $91M
hemodialysis catheter-related bloodstream infectionssource ↗
▲Enrollment CompleteREZZAYOTrial
Enrollment completed in Phase III ReSPECT trial for REZZAYO
prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic blood and marrow transplantationsource ↗
◆Oral PresentationPresentation
Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat
▼Equity OfferingCorporate
CorMedix makes $5M strategic minority equity investment in Talphera
▲Interim Efficacy DataDefenCathApprovedClinical Data
US Renal Care real world evidence interim results: 72% reduction in CRBSI, 70% reduction in hospitalizations
hemodialysis catheter-related bloodstream infectionssource ↗
▼Equity OfferingCorporate
Pricing of underwritten public offering of 6,604,507 shares of common stock for gross proceeds of ~$85 million
▲Product LaunchDefenCathApprovedPost-Market
LDO customer implementation of DefenCath commenced
catheter-related bloodstream infections in dialysis patientssource ↗
◆Oral PresentationPresentation
CorMedix to participate in RBC Capital Markets Global Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How CRMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | REZZAYO | sNDA Submission | sNDA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$184M
Pipeline Value
$1.1B
Commercial Value
Undervalued
Valuation Signal
7
Drugs Scored
1.1x
rNPV / MCap
Top 22%
Micro Cap(rank 146 of 658)
Percentile Rank
CorMedix Inc. carries a moderate pipeline score (48/100), with $459M risk-adjusted pipeline value, led by Single-Dose Oritavancin Diphosphate in Healthy (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $462.2M x 2.3 = $1.1B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| DefenCath | $344M | - | - |
| Melinta Portfolio | $98M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Single-Dose Oritavancin Diphosphate Small moleculeCompletedNCT01252732 | Wound Infection | Phase 3 | COMPLETED | 1,987 | Jun 1, 2013 |
Clinical Trial Results
Readouts, endpoints and source filings for every CRMD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| REZZAYO | prophylaxis of invasive fungal diseases in allogeneic hematopoietic stem cell transplantation patients | Phase 3 | 2026-04-27 | rezafungin fungal free survival: 60.7%; standard antimicrobial regimen fungal free survival: 59.0%Read More | CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation PatientsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Dillione JanetDirector | Option | 48,909 117,835 held | $0.00 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CRMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 0.7 % | 49.25 M | 6.27 M |
CRMD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CRMD ranks across every disease it competes in
Competitive Position is a premium feature
See how CRMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCRMD News
CRMDCorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
CorMedix Therapeutics announced its participation in the Wells Fargo 21st Annual Healthcare Conference, scheduled for September 8-10, 2026, in Boston. Senior management will engage in a fireside chat and investor meetings. A replay of the chat will be accessible on the company's investor relations webpage.
Read more →CRMD▲ +14.6%on this news
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics reported solid financial results for Q2 2026, with consolidated revenue reaching $101.9 million and net income of $26.0 million. The company anticipates an FDA submission for REZZAYO's expanded indication in the third quarter. Additionally, CorMedix has raised its full-year adjusted EBITDA guidance, reflecting confidence in its business outlook.
Read more →CRMDCorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
CorMedix Therapeutics will announce its second quarter financial results on August 13, 2026, before market opening. The company will also conduct a corporate update conference call at 8:30 AM ET. CorMedix is dedicated to developing therapeutic products for serious health conditions in the U.S.
Read more →CRMDU.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
CorMedix Therapeutics announced that the U.S. Court of Appeals upheld the validity of its MINOCIN® patents, affirming a previous district court ruling. The decision prevents Nexus Pharmaceuticals from marketing its generic version of minocycline until the patents expire. This ruling reinforces the importance of protecting pharmaceutical innovations and validates CorMedix's intellectual property efforts.
Read more →CRMDCormedix Therapeutics to Participate in two Upcoming Investor Conferences
CorMedix Therapeutics has announced its participation in the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference, both hosted in New York. The events will allow the company's management to engage in discussions through fireside chats and investor meetings. These conferences are set for May 19-20 and June 2-4, 2026, respectively, providing a platform for CorMedix to showcase its commitment to developing therapeutic products for severe medical conditions.
Read more →CRMD▲ +5.7%on this newsshared move
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics reported a strong financial performance for the first quarter of 2026, posting a net revenue of $127.4 million, driven by solid sales of its DefenCath product. The company also increased its full-year 2026 revenue guidance, reflecting confidence in demand trends and ongoing clinical developments. A successful Phase III trial of REZZAYO could lead to a significant market opportunity in the coming years. However, rising operating expenses, primarily due to the Melinta acquisition, present a concern moving forward.
Read more →CRMDCorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
CorMedix Therapeutics will announce its first quarter financial results on May 14, 2026, before market opening. The company will also host a corporate update conference call at 8:30 AM ET. CorMedix is dedicated to developing therapeutic products for critical health conditions in the U.S.
Read more →CRMD▲ +5.4%on this news
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
CorMedix Therapeutics announced positive topline results from the Phase III ReSPECT trial, demonstrating that REZZAYO (rezafungin) is non-inferior to standard antimicrobial regimens for preventing invasive fungal diseases in allogeneic HSCT patients. The study showed favorable outcomes regarding safety and tolerability, with a significant market opportunity anticipated for the drug. The company plans to submit a supplemental New Drug Application to the FDA in the second half of 2026.
Read more →CRMDCorMedix to Participate in Needham Virtual Healthcare Conference
CorMedix Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. Senior management will engage in a fireside chat and investor meetings. The company focuses on therapeutic products for life-threatening conditions, including their product DefenCath for preventing catheter-related infections. They also have ongoing clinical studies and a portfolio of anti-infective products.
Read more →CRMD▼ -11.5%on this news
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CorMedix Inc. announced its financial results for Q4 and full-year 2025, reporting a net revenue of $128.6 million for the quarter and a pro forma total revenue of $401.3 million for the year. The company achieved a net income of $14.0 million in Q4, driven by strong sales of its product DefenCath. CorMedix also reiterated its guidance for 2026, aiming for net revenue between $300 and $320 million.
Read more →CRMDCorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
CorMedix Inc. will announce its fourth quarter and full year 2025 financial results on March 5, 2026. The company will also host a corporate update conference call at 8:30 AM ET. CorMedix focuses on developing therapeutic products for life-threatening conditions and has a portfolio of anti-infective products following its acquisition of Melinta Therapeutics.
Read more →CRMDNOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Corporate Presentation March 2026 CorMedix Therapeutics NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTIC
CorMedix Therapeutics has presented a corporate overview for March 2026, highlighting its focus on innovative pharmaceutical products for institutional markets. The presentation includes forward-looking statements regarding the company's growth strategy, product pipeline, and financial projections. CorMedix anticipates revenue between $300 and $320 million in 2026 and has a specialty portfolio aimed at addressing significant market opportunities. The company emphasizes its leadership team's experience in driving commercial success and plans for further market developments.
Read more →CRMDCorMedix to Participate in Upcoming Investor Conferences
CorMedix Therapeutics (Nasdaq: CRMD) announced its participation in upcoming investor conferences in March. The company focuses on developing therapeutic products for life-threatening conditions and is commercializing DefenCath for preventing catheter-related bloodstream infections. Following its acquisition of Melinta Therapeutics, CorMedix is expanding its portfolio of anti-infective products and has ongoing clinical studies, including a Phase III study for REZZAYO.
Read more →CRMD▲ +5.3%on this news
CorMedix Therapeutics Announces Share Repurchase Program
CorMedix Therapeutics has announced a share repurchase program authorizing up to $75 million of its common stock. The program is set to run until December 31, 2027, and aims to return value to shareholders while maintaining financial flexibility for business investments. The company expects to start repurchasing shares in Q1 2026.
Read more →CRMDCorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
CorMedix Therapeutics will host an in-person and virtual analyst day on February 10, 2026, in New York. The event will feature presentations on the company's pipeline and growth drivers, including updates on its Phase III programs for REZZAYO and DefenCath. Analysts and institutional investors can register for the event to gain insights into the company's strategies and market dynamics.
Read more →CRMDCorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CorMedix Therapeutics will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company focuses on developing therapeutic products for life-threatening diseases and has a diverse portfolio, including DefenCath for preventing catheter-related infections. They are also advancing clinical studies for various products, with significant results expected in the near future.
Read more →CRMD▼ -32.8%on this newsshared move
CorMedix Therapeutics Announces Leadership and Board Updates
CorMedix Therapeutics has announced significant leadership updates, including CEO Joseph Todisco signing an extended contract and transitioning to Chairman of the Board. The company appointed Mike Seckler as the new EVP & Chief Commercial Officer, bringing extensive experience from various therapeutic areas. These changes are intended to strengthen the company and enhance its potential for future growth, particularly with a diversified product pipeline in development. The board's restructuring reflects the company’s ongoing evolution into a more robust commercial entity.
Read more →CRMD▼ -32.8%on this newsshared move
THERAPEUTICS announces preliminary Fourth quarter and full year 2025 results and provides business updates
CorMedix Therapeutics has announced preliminary financial results for the fourth quarter and full year of 2025, highlighting an unaudited net revenue of approximately $127 million. The company saw its pro forma net revenue reach around $400 million, with an adjusted EBITDA expected between $77 million and $81 million. CEO Joseph Todisco expressed optimism regarding the company’s transformation into a multi-product entity, which is anticipated to strengthen shareholder value. CorMedix also has active ongoing clinical studies for its products, including DefenCath and REZZAYO, with future results expected.
Read more →CRMDCorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
CorMedix Therapeutics announced positive interim results from its real-world evidence study of DefenCath, which reduces catheter-related bloodstream infections (CRBSI) in hemodialysis patients. The study, part of a collaboration with U.S. Renal Care, indicates a 72% reduction in CRBSI and a 70% decrease in related hospitalizations, suggesting significant benefits for patient care and healthcare costs. This data is expected to facilitate discussions with payers to expand access and reimbursement strategies. The study is ongoing, with continued evaluations of additional data points planned for the future.
Read more →CRMDCorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
CorMedix Inc. reported strong financial results for Q3 2025, achieving net revenue of $104.3 million and a net income of $108.6 million. The company raised its FY 2025 pro forma net revenue guidance to a range of $390 to $410 million. However, operating expenses surged due to costs associated with the Melinta acquisition and increased R&D investments.
Read more →About CorMedix Inc.
Headquarters389 INTERPACE PKWY, SUITE 450, PARSIPPANY, NJ, 07054
BIOPHARMAWATCH ELITE PLUS
Trade the next CRMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime